Related references
Note: Only part of the references are listed.Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J. Marks et al.
LANCET NEUROLOGY (2008)
Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum
Christopher D. Herzog et al.
MOLECULAR THERAPY (2008)
Convective delivery of glial cell line-derived neurotrophic factor in the human putamen
Paul F. Morrison et al.
JOURNAL OF NEUROSURGERY (2007)
AAV2 - mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson's disease
Mehdi Gasmi et al.
NEUROBIOLOGY OF DISEASE (2007)
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial
Michael G. Kaplitt et al.
LANCET (2007)
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys
Christopher D. Herzog et al.
MOVEMENT DISORDERS (2007)
Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease
Mehdi Gasmi et al.
MOLECULAR THERAPY (2007)
Point source concentration of GDNF may explain failure of phase II clinical trial
Michael F. Salvatore et al.
EXPERIMENTAL NEUROLOGY (2006)
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
Jeffrey H. Kordower et al.
ANNALS OF NEUROLOGY (2006)
Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC
Krystof S. Bankiewicz et al.
MOLECULAR THERAPY (2006)
Immune responses to AAV in a phase I study for Canavan disease
S. W. J. McPhee et al.
JOURNAL OF GENE MEDICINE (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Crossroads in GDNF therapy for Parkinson's disease
TB Sherer et al.
MOVEMENT DISORDERS (2006)
Adeno-associated virus (AAV) vectors in the CNS
TJ McCown
CURRENT GENE THERAPY (2005)
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor
JT Slevin et al.
JOURNAL OF NEUROSURGERY (2005)
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease
SS Gill et al.
NATURE MEDICINE (2003)
Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys
N Maswood et al.
NEUROBIOLOGY OF AGING (2002)
Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease
Y Oiwa et al.
BRAIN RESEARCH (2002)
Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration
S Palfi et al.
JOURNAL OF NEUROSCIENCE (2002)
Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor
D Kirik et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2000)
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
JH Kordower et al.
SCIENCE (2000)
Share Paper
